MedTrace Logo

Biomarkers for Post-COVID Conditions

NCT05196516 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 208

Last updated 2025-02-11

No results posted yet for this study

Summary

The COVID-19 infection affects humans differently. While some recover quickly and fully, others develop serious illnesses and late complications. The term late complications describe symptoms that last for 12 weeks or longer after COVID-19 infection is detected. The aim of the present project is to investigate whether it is possible to identify genetic factors that occur more frequently in people suffering from COVID-19 late complications than in those who do not develop late complications. The investigators aim to develop a genetic profile that identifies individuals at high risk for late complications of COVID-19. Number and nature of late complications will be analysed to identify patterns in the incidence of late complications associated with certain genetic traits. The study is designed as a case-control study and is expected to include 500 subjects between 18 and 65 years of age who at least 12 weeks ago tested positive for COVID-19; 250 who suffer from late complications and 250 who have fully recovered.

Conditions

Sponsors & Collaborators

  • Mental Health Services in the Capital Region, Denmark

    collaborator OTHER

  • Skane University Hospital

    collaborator OTHER

  • Zealand University Hospital

    lead OTHER

Principal Investigators

  • Gesche Jürgens, Associate Professor, Ph.D., MD · Clinical Pharmacology Unit, Zealand University Hospital, Roskilde, Denmark

  • Thomas Werge, Professor, Ph.D. · Institute of Biological Psychiatry, Sct. Hans Hospital, Capital Region, Denmark

  • Fredrik Kahn, Associate Professor, Ph.D., MD · Department of infectious disease, Skåne University Hospital, Sweden

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-13
Primary Completion
2022-09-23
Completion
2022-09-23

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05196516 on ClinicalTrials.gov